Evidence map›Paper›PMID 33914661›Full record

Trial reportJournal of applied physiology (Bethesda, Md. : 1985)2021

The effect of long-acting dual bronchodilator therapy on exercise tolerance, dynamic hyperinflation, and dead space during constant work rate exercise in COPD.

William W Stringer, Janos Porszasz, Min Cao, Harry B Rossiter, Shahid Siddiqui, Stephen Rennard, Richard Casaburi

Registry-linked trialOpen access · hybridAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of applied physiology (Bethesda, Md. : 1985), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03081156 (An Investigator Initiated, Randomized, Double Blind, Placebo Controlled Study to Assess the Effect of Glycopyrrolate/Formoterol on Exercise Tolerance and Dynamic Hyperinflation in Patients With Chronic Obstructive Pulmonary Disease.), which is not on this map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03081156 phase4completednot on this map

An Investigator Initiated, Randomized, Double Blind, Placebo Controlled Study to Assess the Effect of Glycopyrrolate/Formoterol on Exercise Tolerance and Dynamic Hyperinflation in Patients With Chronic Obstructive Pulmonary Disease.

TypeinterventionalSponsorWilliam Stringer, mdRan2017 to 2019Enrolled52ConditionsPulmonary Disease, Chronic ObstructiveArmsGlycopyrrolate / Formoterol Inhaler vs Placebo Inhaler
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it, 11 citations in OpenAlex.

  1. Fixed-intensity exercise tests to measure exertional dyspnoea in chronic heart and lung populations: a systematic review.European respiratory review : an official journal of the European Respiratory Society · 2023
    Pooled it
  2. Pooled it
  3. Trial
  4. CPET Characteristics in HFrEF, HFpEF and COPD.Journal of clinical medicine · 2026
    Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

William W StringerThe Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California.ORCID 0000-0003-2756-6728
Janos PorszaszThe Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California.
Min CaoThe Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California.
Harry B RossiterThe Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California.
Shahid SiddiquiRegeneron, Tarrytown, New York.
Stephen RennardBioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.
Richard CasaburiThe Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California.
UCLA Medical Center · USAstraZeneca (United Kingdom) · GBRegeneron (United States) · USUniversity of Leeds · GB

Funding

Determinants of 5 Year Progression of Muscle Dysfunction and Inactivity in COPDGene Participants Diversity SupplementR01HL151452 · NHLBI · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI ADAMI, ALESSANDRA, ROSSITER, HARRY B · 2020 to 2023
$1.6M
6 · The paper itself

Abstract

We investigated whether dual bronchodilator therapy (glycopyrrolate/formoterol fumarate; GFF; Bevespi Aerosphere) would increase exercise tolerance during a high-intensity constant work rate exercise test (CWRET) and the relative contributions of dead space ventilation (V

Indexed as

Bronchodilator AgentsPulmonary Disease, Chronic ObstructiveDouble-Blind MethodExercise ToleranceForced Expiratory VolumeGlycopyrrolateHumansMaleBronchodilator AgentsGlycopyrrolateCOPDCPETexercise intolerancehyperinflationVD/VT

Identifiers

PMID33914661
PMCPMC8526332
OpenAlexW3158150698

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.